Search clinical trials for: Moderate plaque psoriasis,

Total 20254 results

AbbVie

Recruiting

An Observational Study to Validate the Cumulative Life Course Impairment (CLCI) Instrument (DermCLCI-p) in Adult Participants With Moderate to Severe Chronic Plaque Psoriasis (PsO) (IMMagine)

Psoriasis

Canada, Belgium, Germany
AbbVie

Terminated

A Study to Assess Adverse Events and Disease Activity With Cedirogant (ABBV-157) in Adult Participants With Moderate to Severe Psoriasis

Psoriasis

United States, Canada, Japan
Innovaderm Research Inc.
Ciusss de L'Est de l'Île de Montréal

Withdrawn

Effect of Bimekizumab in Patients With Psoriasis Vulgaris and Active Psoriatic Arthritis

Psoriasis Vulgaris | Active Psoriatic Arthritis
Can-Fite BioPharma

Completed

Trial of CF101 to Treat Patients With Psoriasis

Plaque Psoriasis

Israel, United States, Bulgaria, Romania
University of California, San Francisco
Novartis Pharmaceuticals; National Psoriasis Foundation

Recruiting

Dermatologic Research Evaluation and Monitoring of Sleep in Moderate-to-Severe Psoriasis (DREAMS-PSO)

Psoriasis Vulgaris

United States
Postgraduate Institute of Medical Education and...

Unknown

Comparison of Oral Versus Subcutaneous Route of Methotrexate Administration in Moderate to Severe Psoriasis

Psoriasis Vulgaris
LEO Pharma

Completed

Effect of LEO 90100 on the HPA Axis and Calcium Metabolism in Subjects With Extensive Psoriasis VulgarisExtensive Psoriasis Vulgaris

Psoriasis Vulgaris

Canada
Pfizer

Completed

A 12 Day Study To Evaluate A Topical Drug To Treat Plaque Psoriasis

Psoriasis Vulgaris

Germany
Technische Universität Dresden

Completed

Evaluation of Topical Antipsoriatics in the Psoriasis Plaque Test

Psoriasis Vulgaris

Germany
AstraZeneca

Terminated

Study to Determine if AZD0284 is Effective and Safe in Treating Plaque Psoriasis (DERMIS)

Plaque Psoriasis Vulgaris

Denmark
Can-Fite BioPharma

Completed

Safety and Efficacy Study of CF101 to Treat Psoriasis

Plaque Psoriasis

Israel
Pfizer

Completed

Safety Study of Ointment for the Treatment of Plaque-type Psoriasis (AN2728-PSR-104)

Plaque-type Psoriasis

Australia
The Catholic University of Korea

Unknown

Microneedle Patch for Psoriatic Plaques

Psoriasis | Administration, Topical

Korea, Republic of
OPKO Health, Inc.

Completed

Safety and Efficacy of Topically Applied CTA018 in Plaque Psoriasis

Psoriasis

United States
TetraLogic Pharmaceuticals

Completed

SHP-141C in Plaque Type Psoriasis

Plaque Type Psoriasis

Australia
Almirall, S.A.

Completed

Efficacy and Safety of Tildrakizumab in Participants With Moderate-to-Severe Chronic Plaque Psoriasis Who Are Non-Responders to Dimethyl Fumarate Therapy (TRANSITION)

Plaque Psoriasis

United Kingdom, Germany
MetrioPharm AG
Parexel

Completed

Study to Evaluate Safety and Efficacy of Oral MP1032 in Psoriasis Patients

Psoriasis | Plaque Psoriasis

Germany
ApoPharma

Completed

Study to Evaluate Apo805K1 in Subjects With Moderate to Severe Chronic Plaque Psoriasis

Plaque Psoriasis

United States, Canada
Genesis Pharma S.A.
Celgene

Completed

A Study of Treatment With APRemilast in Moderate psoriAsIS in Real Life clinicAL Practice (The 'APRAISAL' Study) (APRAISAL)

Moderate Plaque Psoriasis

Greece
AbbVie

Completed

Study of Subcutaneous Risankizumab Injection Compared to Oral Apremilast Tablets to Assess Change in Disease Activity And Adverse Events in Adult Participants With Moderate Plaque Psoriasis Who Are Candidates for Systemic Therapy

Psoriasis

United States, Canada, Germany, Israel, Poland
Tufts Medical Center
Immune Control

Completed

Fluphenazine Hydrochloride for Psoriasis (FP-CL2)

Psoriasis

United States
King's College London
Psoriasis Association

Recruiting

The Mediterranean Diet and Time-Restricted Eating Dietary Interventions for Psoriasis Study (METRED-P)

Psoriasis Vulgaris

United Kingdom
King's College London
Psoriasis Association

Completed

Asking People With Psoriasis About Lifestyle and Eating (APPLE)

Psoriasis

United Kingdom
ISDIN

Completed

Efficacy and Tolerability Study of Topical Ciclosporin in a Psoriasis Plaque Test

Psoriasis

Germany
Idera Pharmaceuticals, Inc.

Completed

A 12-week Dose-Ranging Trial in Patients With Moderate to Severe Plaque Psoriasis (8400-201)

Plaque Psoriasis

Netherlands
Bristol-Myers Squibb

Not yet recruiting

Real-World Safety and Effectiveness of Sotyktu (Deucravacitinib) in Patients With Moderate-to-Severe Plaque Psoriasis in Korea

Moderate-to-severe Plaque Psoriasis

Korea, Republic of
Kyowa Kirin Korea Co., Ltd.

Completed

A Study of KHK4827 (Brodalumab) in Subjects With Moderate to Severe Psoriasis in Korea

Moderate to Severe Plaque Psoriasis

Korea, Republic of
UCB Biopharma SRL

Completed

A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Korean Study Participants With Moderate to Severe Plaque Psoriasis

Moderate to Severe Plaque Psoriasis

Korea, Republic of
Novartis Pharmaceuticals

Completed

A Study of Moderate-to-severe Plaque Psoriasis Patients Response to Secukinumab Treatment in Real-world Setting

Moderate-to-severe Plaque Psoriasis

Indonesia
AbbVie (prior sponsor, Abbott)

Completed

Documentation of Humira in Psoriasis Patients in Routine Clinical Practice (LOTOS)

Moderate to Severe Plaque Psoriasis

Germany
Sunshine Guojian Pharmaceutical (Shanghai) Co.,...

Unknown

Randomized, Double Blinded, Placebo Controlled, Single Dose Escalation Study of 608 in Healthy Subjects

Moderate to Severe Plaque Psoriasis

China
Jiangsu HengRui Medicine Co., Ltd.

Unknown

A Safety Study of Multiple Subcutaneous (s.c.) Injections of SHR-1314 in Adults With Moderate-to-severe Plaque Psoriasis

Moderate-to-severe Plaque Psoriasis

China
AbbVie (prior sponsor, Abbott)

Completed

Effectiveness of Adalimumab (HUMIRA®) in the Treatment of Scalp and Nail Affection in Patients With Moderate to Severe Plaque Psoriasis in Routine Clinical Practice

Moderate to Severe Plaque Psoriasis

Czech Republic, Estonia, Hungary, Israel, Romania, Slovakia, Slovenia, Ukraine
AbbVie (prior sponsor, Abbott)

Completed

Open Label Continuation Study in Moderate to Severe Psoriasis

Moderate to Severe Plaque Psoriasis

United States, Austria, Belgium, Canada, Denmark, Finland, France, Germany, Greece, Italy, Spain, Sweden, Switzerland, United Kingdom
Abbott

Withdrawn

Open Label, Single Dose, Non-randomized Study to Assess the Drug to Drug Interaction of Briakinumab on CYP Substrates.

Moderate to Severe Plaque Psoriasis
LEO Pharma

Completed

Efficacy and Tolerability of Enstilar® in Daily Practice

Plaque Psoriasis

Germany
Amgen

Completed

Efficacy and Safety Study of Apremilast (CC-10004) in Subjects With Moderate-to-Severe Plaque-Type Psoriasis (Core Study)

Psoriasis | Plaque-type Psoriasis

United States, Canada
Samsung Bioepis Co., Ltd.
Organon and Co

Completed

Pharmacokinetics, Efficacy, Safety, and Immunogenicity of SB5 Versus Humira in Subjects With Moderate to Severe Chronic Plaque Psoriasis

Plaque Psoriasis

Czechia, Lithuania, Poland, Bulgaria
Tianjin Hemay Pharmaceutical Co., Ltd

Completed

Efficacy and Safety Study of Hemay005 in Subjects With Moderate to Severe Plaque Psoriasis

Psoriasis

China
Beijing InnoCare Pharma Tech Co., Ltd.

Recruiting

Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of ICP-488 in Patients With Moderate to Severe Plaque Psoriasis

Moderate to Severe Plaque Psoriasis

China
Jiangsu HengRui Medicine Co., Ltd.

Not yet recruiting

Efficacy 、Safety and PK of SHR-1314 in Patients With Moderate-to-Severe Plaque Psoriasis

Moderate-to-Severe Plaque Psoriasis
Sun Pharmaceutical Industries Limited

Recruiting

To Assess the Effect of SCD-044 Treatment on Moderate to Severe Plaque Psoriasis (SOLARES-PsO-1)

Moderate to Severe Plaque Psoriasis

United States, El Salvador
Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Completed

A Clinical Study to Compare the Safety and Pharmacokinetics of SHR-1314 Injection in Healthy Subjects at Different Specifications Devices

Moderate-to-Severe Plaque Psoriasis

China
Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Active, not recruiting

A Phase 2 Study of Jaktinib in Participants With Moderate to Severe Psoriasis (PSO)

Moderate-to-Severe Plaque Psoriasis

China
Hangzhou Highlightll Pharmaceutical Co., Ltd

Completed

Safety and Efficacy of TLL018 in Patients With Plaque Psoriasis

Moderate to Severe Plaque Psoriasis

China
Cadila Pharnmaceuticals
Lipidor AB, Svärdvägen 13 SE-182 33 Danderyd, Sweden

Completed

A Clinical Trial to Evaluate Efficacy and Safety of Two Different Formulations of Topical Calcipotriol in Patients With Mild to Moderate Plaque Psoriasis (AKP01)

Mild to Moderate Plaque Psoriasis

India
Kyowa Kirin Co., Ltd.
Kyowa Hakko Kirin China Pharmaceutical Co., LTD.

Withdrawn

A Phase 4 Study of Brodalumab (KHK4827) in Subjects With Moderate to Severe Plaque Psoriasis

Moderate to Severe Plaque Psoriasis

China
Novartis Pharmaceuticals

Completed

Investigate Effect of Secukinumab on the PK of Midazolam in Patients With Mod to Sev Plaque Psoriasis

Moderate to Severe Plaque Psoriasis

United States
Novartis Pharmaceuticals

Completed

A 24-week, Multicenter, proSpective stUdy to Evaluate the PASI 90 Clinical Response Rate and the Safety PRofile of sEcukinuMab 300 mg in Cw6-negativE and Cw6-positive Patients With Moderate to Severe Chronic Plaque-type Psoriasis (SUPREME) (SUPREME)

Plaque Type Psorisis

Italy
Sun Pharmaceutical Industries Limited

Completed

A Study to Evaluate the Efficacy and Safety/Tolerability of Subcutaneous Tildrakizumab (SCH 900222/MK-3222) in Participants With Moderate-to-Severe Chronic Plaque Psoriasis Followed by a Long-term Extension Study (MK-3222-011) (reSURFACE 2)

Plaque Psoriasis

3

Subscribe